What's in Syntrillo, Inc's pipeline?

Syntrillo, Inc has 3 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 3 in Phase 1.

Which companies overlap with Syntrillo, Inc's portfolio?

Top competitors by shared drug class: Korea University Guro Hospital, Samsung Medical Center.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/syntrillo-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Syntrillo, Inc — Portfolio Competitive Intelligence Brief

Syntrillo, Inc pipeline: 0 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Korea University Guro Hospital · 1 shared drug class
Samsung Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Syntrillo, Inc:

Cite this brief

Drug Landscape (2026). Syntrillo, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/syntrillo-inc. Accessed 2026-05-16.